Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy

European Journal of Dermatology

Volumn 16, Issue 6, 2006, Pages 623-635

  Bonnekoh, Bernd ^a   Malykh, Yanina ^b   Böckelmann, Raik ^a   Bartsch, Sebastian ^b   Pommer, Ansgar J ^b,c   Gollnick, Harald ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MelTec GmbH and Co KG   (Germany)

^c SkinSysTec GmbH   (Germany)

Author keywords

Biologicals; CD11a; Cytometry; MELC toponomics; Multiplex fluorescence immunophenotyping; Proteomics

Indexed keywords

ANTIGEN; CD 247 ANTIGEN; CD11 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD52 ANTIGEN; CD8 ANTIGEN; EFALIZUMAB; HERMES ANTIGEN; HLA DR ANTIGEN; LECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; EPITOPE MAPPING; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTE; MULTI EPITOPE LIGAND CARTOGRAPHY ROBOT MICROSCOPY; MULTICENTER STUDY; PSORIASIS; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD11; ANTIGENS, CD11A; BINDING SITES; EPITOPES; HUMANS; LEUKOCYTE COUNT; LIGANDS; LYMPHOCYTE SUBSETS; PSORIASIS; ROBOTICS; TREATMENT OUTCOME;

EID: 33846840961     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0005     Document Type: Article

References (28)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
2. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T-cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin homing CD8(+) T-cells. Clin Exp Immunol 2004; 138: 83-93.
3. Böckelmann R, Horn T, Gollnick H, Bonnekoh B. Interferon-γ- dependent in-vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects. Skin Pharmacol Physiol 2005; 18: 42-54.
4. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75.
5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
6. Bonnekoh B, Gollnick H. Psoriasis. In: Katsambas AD, Lotti TM, eds. European Handbook of Dermatological Treatment. 2. Ed. Berlin: Springer, 2003: 433-50.
7. Bonish BK, Nickoloff BJ. Immunopathogenesis - Psoriasis. In: Gordon KB, Ruderman EM, eds. Psoriasis and psoriatic arthritis - an integrated approach. Berlin: Springer, 2005: 23-35.
8. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler D, Finlay AV, Grifitths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-97.
9. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105: 105-16.
10. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-7.
11. Mease PJ, Goffe BS, Metz J, Van der Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 385-90.
12. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
13. Jullien D, Prinz JC, Langley RGB, Caro I, Dummer W, Joshi A, Dedrick R, Natta P. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 2004; 208: 297-306.
14. Leonardi CL. Efalizumab, an overview. J Am Acad Dermatol 2003; 49(suppl 2): S98-S104.
15. Marecki S, Kirkpatrick P. Efalizumab. Nat Rev Drug Discov 2004; 3: 473-4.
16. Papp K, Bissonnette R, Krueger JG, Carvey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-74.
17. Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Böckelmann R, Malykh Y, Gollnick H, Friedenberger M, Bode M, Dress AWM. Analyzing proteome topology and function by automated multi-dimensional fluorescence microscopy. Nat Biotechnol 2006; 24: 1270-8.
18. Bonnekoh B, Böckelmann R, Pommer AJ, Malykh Y, Philipsen L, Gollnick H. The CD11a binding site of efalizumab in psoriatic skin tissue as analysed by multi epitope ligand cartography (MELC) robot technology: introduction of a novel biological drug binding biochip assay. Skin Pharmacol Physiol 2007; 20: 96-111.
19. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unraveling the immune system. Nat Rev Immunol 2004; 4: 648-55.
20. Bovenschen UJ, van de Kerkhof PCM, Gerritsen WJ, Seyger MMB. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy. Eur J Dermatol 2005; 15: 454-8.
21. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware Jr. JE. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004; 3: 27-38.
22. Desroches CV, Andreoni C, Rigal D. Differential expression of the LFA-1 molecule on the human peripheral blood mononuclear cell subpopulations. Immunol Lett 1990; 24: 13-20.
23. Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, Pippig S. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004; 310: 896-904.
24. Lowes MA, Turton JA, Krueger JG, Barnetson R. StC. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol 2005; 5: 9.
25. Bauer RJ, Russel DL, White RL, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999; 27: 397-420.
26. Gottlieb AB, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-35.
27. Halliday JA, Franks AH, Ramsdale TE, Martin R, Palant E. A rapid, semi-automated method for detection of Galbeta1-4GlcNAc alpha2,6- sialyltransferase (EC 2.4.99.1) activity using the Sambucus nigra agglutinin. Glycobiology 2001; 11: 557-64.
28. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, Krueger JG, Leonardi C, Miller B, Joshi A. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005; 45: 286-98.